New study: can a single shot help fight advanced breast cancer by shutting down ovaries?
NCT ID NCT07310420
First seen Jan 03, 2026 · Last updated May 09, 2026 · Updated 21 times
Summary
This early-stage trial is testing a single injection of ZOLADEX 10.8 mg to temporarily stop the ovaries from producing hormones in premenopausal women with a certain type of advanced breast cancer (HR+/HER2-). The goal is to see if the drug can effectively suppress ovarian function, which may help control the cancer. The study will enroll 88 women and measure hormone levels and menstrual activity over 24 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duly Health and Care
Lisle, Illinois, 60532, United States
-
Presence Infusion Care
Skokie, Illinois, 60077, United States
-
Profound Research LLC at Michigan Hematology and Oncology Consultants
Royal Oak, Michigan, 48073, United States
Conditions
Explore the condition pages connected to this study.